This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Progressive supranuclear palsy (PSP) encompasses a range of clinical phenotypes presenting with preeminent movement, behavioral, and cognitive abnormalities. PSP is a rare disease, with prevalence estimates ranging between 5 and 18 cases per 100,000 people,1 although it is still largely underdiagnosed in clinical settings.2 No curative treatment has been identified for this condition; management still relies on pharmacologic (e.g., antiparkinsonian therapies) and nonpharmacologic (e.g., physical and speech therapy) symptomatic and supportive interventions.1 To date, according to the clinicaltrials.gov registry, 10 research protocols are testing the efficacy and safety profile of novel compounds (i.e., anti-tau monoclonal antibodies, microtubule stabilizers, inhibitors of tau acetylation, and rejuvenation therapies) with potential disease-modifying effect.
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 241
- © 2019 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Topics Discussed
Alert Me
Recommended articles
Language boosting by transcranial stimulation in progressive supranuclear palsy
Classification of primary progressive aphasia and its variants
Longitudinal structural and metabolic changes in frontotemporal dementia
Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum